Fox Chase Cancer Center (FCCC) is the proven birthplace for groundbreaking basic and clinical research that led to the discovery of the Philadelphia chromosome and two Nobel Prizes. FCCC is one of the only 41 cancer centers nationwide that qualify as National Cancer Institute (NCI)-designated Comprehensive Cancer Center – the top designation that provides funding supports for multidisciplinary state-of-the-art core facilities that empowers FCCC investigators.

The Lu Chen lab is part of **Cancer Epigenetics Institute (CEI-FCCC)** that offers rich resources in training, mentorship, and career development. The institute hosts regular "From Paper to the Scientist" workshops and annual research symposiums – various forums that bring world-leading epigenetic experts to trainees in face-to-face discussions. In addition, CEI bridges collaborations among academic, industry, and clinics aiming to leverage epigenetics to combat cancer growth and drug resistance. Notable success includes the recent clinical trial expansion of a lead epigenetic drug at Fox Chase for treating sarcomas.

A postdoctoral position is immediately available in **the Lu Chen lab** of the Cancer Signaling and Epigenetic Program. The lab aims to understand in molecular details how misregulated RNA biology can contribute to human conditions, including cancer, aging, and degenerative diseases, with a long-term goal to design RNA-centric therapeutics to improve public health. We currently study RNP structure-function, RNA modifications and subcellular trafficking using multidisciplinary approaches, including RNP biochemistry, high-throughput RNA structural mapping, cell imaging, and genetic modeling in cellular and animal models. The lab is well-equipped with top-the-line instruments and is staffed with one postdoctoral fellow and the PI. Lu Chen has a proven track record of publishing high impact research (9 papers as 1st author, 2 as corresponding author), and a solid record in mentoring trainees and in collaborations. The ongoing research projects includes two *manuscripts in preparation* and other preliminary results, and new directions that can be tailored to specialized research interests.

Selected Publication:

Chen L*, Chang HY, and Artandi SE. *Analysis of RNA conformation in endogenously assembled RNPs by icSHAPE*. **STAR Protocols** 2 (2), 100477 (***co-corresponding author**)

Chen L*, Bellone RR, Wang Y, Singer-Berk M, Ford JM, Artandi SE. *A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.* **DNA Repair** 2020 Nov 12 (*** corresponding author**)

Chen L, Roake CM, Galati A, Bavasso F, Saggio I, Schoeftner S, Cacchione S, Gatti, M, Artandi SE*, Raffa GD*. *Loss of Human TGS1 Hypermethylase Promotes Increased Telomerase RNA and Telomere Elongation.* **Cell Reports** 2020 Feb 04; 30: 1358-1272

Chen L, Roake CM, Freund A, Batista PJ, Tian S, Yin, YA, Gajera C, Lin S, Lee B, Pech M, Venteicher AS, Das R, Chang HY, Artandi SE. *An activity switch in human telomerase dependent on RNA conformation and shaped by TCAB1*. **Cell.** 2018 Jun 28

We welcome like-minded colleagues that share passion and dedication in science and discovery, especially those who show a clear vision and commitment to a productive future research career. Candidates with a PhD or equivalent and a relevant publication record should send CV, a brief description of research interests, and names of 3 references to email: luchenlab@yahoo.com. For more up-to-date information, please visit www.luchenlab.org, and follow @luchenlab_FCCC